Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2017 - 2022)
Historic Non-Current Deffered Revenue for Denali Therapeutics (DNLI) over the last 6 years, with Q4 2022 value amounting to $479000.0.
- Denali Therapeutics' Non-Current Deffered Revenue fell 8590.35% to $479000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $479000.0, marking a year-over-year decrease of 8590.35%. This contributed to the annual value of $479000.0 for FY2022, which is 8590.35% down from last year.
- As of Q4 2022, Denali Therapeutics' Non-Current Deffered Revenue stood at $479000.0, which was down 8590.35% from $3.4 million recorded in Q2 2022.
- In the past 5 years, Denali Therapeutics' Non-Current Deffered Revenue registered a high of $57.4 million during Q4 2018, and its lowest value of $479000.0 during Q4 2022.
- In the last 5 years, Denali Therapeutics' Non-Current Deffered Revenue had a median value of $31.3 million in 2021 and averaged $30.7 million.
- As far as peak fluctuations go, Denali Therapeutics' Non-Current Deffered Revenue surged by 81118.53% in 2018, and later crashed by 8915.14% in 2022.
- Over the past 5 years, Denali Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $57.4 million in 2018, then decreased by 23.71% to $43.8 million in 2019, then tumbled by 46.69% to $23.3 million in 2020, then tumbled by 85.43% to $3.4 million in 2021, then plummeted by 85.9% to $479000.0 in 2022.
- Its last three reported values are $479000.0 in Q4 2022, $3.4 million for Q2 2022, and $3.4 million during Q1 2022.